--- title: "Navidea Biopharmaceuticals, Inc. Files for Bankruptcy | NAVB Stock News" description: "Navidea Biopharmaceuticals, Inc. has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware as of October 1, 2025. The company aims to restructure its financial obli" type: "news" locale: "en" url: "https://longbridge.com/en/news/260330509.md" published_at: "2025-10-08T20:57:00.000Z" --- # Navidea Biopharmaceuticals, Inc. Files for Bankruptcy | NAVB Stock News > Navidea Biopharmaceuticals, Inc. has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware as of October 1, 2025. The company aims to restructure its financial obligations while continuing limited operations to preserve value for creditors and stakeholders. Navidea focuses on developing precision immunodiagnostic agents and immunotherapeutics, utilizing its Manocept platform to enhance diagnostic accuracy and treatment. Epiq Corporate Restructuring, LLC is managing the bankruptcy case, providing information to creditors and interested parties. 10/08/2025 - 04:57 PM *Navidea Biopharmaceucitals, Inc. files for Bankruptcy* COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the “Court”) on October 1, 2025. The filing is intended to enable the Company to pursue an orderly restructuring of its financial obligations while continuing limited operations to preserve value for creditors and stakeholders. The Company intends to use the Chapter 11 process to evaluate strategic alternatives, protect its assets, and ensure fair treatment of creditors. **Access to Case Information** Epiq Corporate Restructuring, LLC (“Epiq”) is serving as the claims and noticing agent for the Company’s Chapter 11 case. Creditors, shareholders, and other interested parties can obtain additional information about the case, including court filings, claim forms, and key dates, by visiting the Epiq website at: https://dm.epiq11.com/Navidea. Additionally, creditors, shareholders, and other interested parties can register on the case website to receive electronic copies of to all docketed Court pleadings, free of charge. **About Navidea** Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts through its diverse portfolio of issued US and foreign patents and patent applications. For more information, visit www.navidea.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20251008843839/en/ Craig A. Dais, Chief Financial Officer cdais@navidea.com (614)-822-2322 Source: Navidea Biopharmaceuticals, Inc. ### Related Stocks - [NAVBQ.US - NAVIDEA BIOPHARMACEUTICALS INC](https://longbridge.com/en/quote/NAVBQ.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 15:18 ET 在 HelloNation，特拉华州米德尔敦的税务规划专家 Sharron Cirillo 为特拉华州企业讲解全年税务规划 | 一篇来自 HelloNation 的文章，由税务规划专家 Sharron Cirillo 撰写，强调了德拉瓦州企业全年税务规划的重要性。文章指出，有效的税务规划是主动的，涉及持续的审查和前瞻性，而不仅仅是满足税务准备的截止日期。文章讨论了持 | [Link](https://longbridge.com/en/news/276076381.md) | | Stonewall 收购了 Architectural Alliance, Inc.并在特拉华州站稳脚跟 | 石墙集团已收购位于特拉华州威尔明顿的知名建筑公司建筑联盟公司（Architectural Alliance, Inc.）。建筑联盟成立于 1987 年，以其以客户为中心的建筑解决方案而闻名，涵盖多个领域。此次合作将使建筑联盟能够保持其品牌和 | [Link](https://longbridge.com/en/news/276060068.md) | | Medexus Pharmaceuticals 公布第三季度财报结果 | Medexus Pharmaceuticals 公布第三季度业绩 | [Link](https://longbridge.com/en/news/275670725.md) | | 在近期股价疲软和长期回报压力下评估 Bio-Rad（BIO）的估值 | Bio-Rad 实验室（BIO）经历了显著的股价下跌，促使对其估值进行重新评估。目前股价为 256.56 美元，相较于 348 美元的公允价值估计，该股票被认为是被低估的。尽管面临近期挑战，包括三年内总股东回报下降 46.91%，Bio-R | [Link](https://longbridge.com/en/news/275997412.md) | | ZAWYA-PRESSR：Mubadala Bio 全资收购 IDS 和 GMSC | Mubadala Bio 已完成对 Al Ittihad Drug Store (IDS) 和 Global Medical Supply Chain (GMSC) 的全面收购，此前在 2024 年进行了 80% 的初步收购。此举旨在通过整 | [Link](https://longbridge.com/en/news/276104719.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.